Abiomed (ABMD) Tops Q3 EPS by 16c; Raises Low End of FY Revenues Guidance

Abiomed (NASDAQ: ABMD) reported Q3 EPS of $1.13, $0.16 better than the analyst estimate of $0.97. Revenue for the quarter came in at $261 million versus the consensus estimate of $253.8 million.

GUIDANCE:

Abiomed sees FY2022 revenue of $1.025-1.03 billion, versus the consensus of $1.02 billion.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance